Table 1. Baseline characteristics of study population based on BMI category.

BMI, body mass index; HR, hormone receptor; HER2, human epidermal growth factor receptor 2; TNBC, triple-negative breast cancer.

Variables	All (n = 69)	BMI < 25 (n = 43)	BMI ≥ 25 (n = 26)	P
BMI, median (range)	23.9 (19.38–44.9)	22.2 (19.38–24.7)	28.8 (25.3–44.9)	<0.001
BRCA mutation, n (%)				0.6
BRCA1	40 (58.0%)	26 (60.5%)	14 (53.8%)
BRCA2	29 (42.0%)	17 (39.5%)	12 (46.2%)
Age, median (range)	40 (25–69)	39.0 (25–60)	44.5 (28–69)	0.03
Diabetes, n (%)				0.4
No	68 (98.6%)	43 (100.0%)	25 (96.2%)
Yes	1 (1.4%)	0 (0%)	1 (3.8%)
Dyslipidemia, n (%)				0.01
No	62 (89.9%)	42 (97.7%)	20 (76.9%)
Yes	7 (10.1%)	1 (2.3%)	6 (23.1%)
Hypertension, n (%)				0.046
No	61 (88.4%)	41 (95.3%)	20 (76.9%)
Yes	8 (11.6%)	2 (4.7%)	6 (23.1%)
Menopausal status, n (%)				0.022
Pre-	46 (66.7%)	33 (76.7%)	13 (50.0%)
Post-	23 (33.3%)	10 (23.3%)	13 (50.0%)
Race, n (%)				0.1
Asian	1 (1.4%)	1 (2.3%)	0 (0.0%)
Black	2 (2.9%)	2 (4.7%)	0 (0.0%)
Other	2 (2.9%)	0 (0.0%)	2 (7.7%)
White	56 (81.2%)	33 (76.7%)	23 (88.5%)
Missing	8 (11.6%)	7 (16.3%)	1 (3.8%)
Invasive tumor present, n (%)				0.7
No	39 (56.5%)	25 (58.1%)	14 (53.8%)
Yes	30 (43.5%)	18 (41.9%)	12 (46.2%)
Tumor subtype, n (%)				>0.9
HR+	22 (31.9%)	14 (32.6%)	8 (30.8%)
HER2+	1 (1.4%)	1 (2.3%)	0 (0.0%)
TNBC	9 (13.0%)	5 (11.6%)	4 (15.4%)
N/A	37 (53.6%)	23 (53.5%)	14 (53.8%)